The review concluded that patient satisfaction was high with medication for gastroesophageal reflux disease and particularly for proton pump inhibitors (more than 70%). There was also a positive association between patient satisfaction and symptom resolution and health-related quality of life. Potential limitations to study quality and the review process imply the authors' conclusions should be treated with caution.
Methods of synthesis
Results were pooled for the trials of PPIs after four weeks treatment to give weighted average percentages with 95% confidence intervals (CI). Subgroup analyses were performed to compare continuous and on-demand proton pump inhibitor therapy, different PPIs and for participants with reflux oesophagitis. Results were pooled for the trials of H 2 RAs. The relationship between patient satisfaction and reflux symptom relief and resolution and changes in HRQoL scores were examined. Separate meta-analyses or narrative summaries were performed for the trials and the surveys. Patient satisfaction: In 12 trials of proton pump inhibitor therapy 57% to 97% patients were satisfied and 56% to 100% patients were very satisfied with their therapy.
Results of the review
A pooled analysis after four weeks proton pump inhibitor treatment found weighted averages of 93% patients (95% CI 87% to 99%) were satisfied and 73% of patients (95% CI 62% to 83%) were very satisfied (eight trials).
Pooled analyses of satisfaction of patients for individual PPIs were 77% (95% CI 61% to 93%; three trails) for omeprazole, 84% (95% CI 72% to 95%; two studies) for lansoprazole, 95% (95% CI 92% to 98%; four studies) for esomeprazole and 79% for one study of pantoprazole; whether differences were important was unclear.
Three trials compared different PPIs. One trial found significantly more patients (5% more) were satisfied with ondemand esomeprazole versus continuous daily lansoprazole. The other trials compared continuous omeprazole, lansoprazole and pantoprazole, and daily rabeprazole versus daily esomeprazole and found no significant differences.
Three of four trials found significantly higher satisfaction for long-term (three to six months) continuous treatment than for on-demand treatment, mainly using esomeprazole. In two trials satisfaction was higher for PPIs than for other GERD medications (significance not reported). Two trials that reported satisfaction with H 2 RAs found that 79% of patients were satisfied and 33% to 34% were very satisfied.
Patient satisfaction, symptom resolution and HRQoL: Seven trials found a positive correlation between patient satisfaction and symptom improvement. The weighted average of patients satisfied with their treatment was 11% higher (95% CI 2.5% to 18.9%; five trials) than that for symptom relief and 10.6% higher (95% CI 2.2% to 19.0%; seven trials) than that for complete symptom resolution.
Authors' conclusions
More than a half of the patients were satisfied with their proton pump inhibitor medication in trials. More patients were satisfied with PPIs than other medication types. An association between patient satisfaction and symptom resolution was found, which suggested that patient satisfaction was a useful end point for evaluating GERD treatment success.
CRD commentary
The review addressed a well-defined question in terms of study design, participants, interventions and relevant outcomes. The search was adequate but did not include unpublished studies and only included studies published in English so some relevant studies could have been missed. There was no assessment of publication bias. There was no formal assessment of study quality and very little relevant information was provided to enable the reader to assess study quality. There was a possibility of error and bias in the review processes as the authors did not report how many reviewers conducted study selection and data extraction.
Some relevant study information was provided but no details of the gender or age of patients were reported. The synthesis combined a narrative review with some meta-analyses. It was unclear whether the meta-analyses were appropriate as reporting was unclear. The authors appropriately considered the results of trials and surveys separately. Most of the trials were of PPIs so conclusions for other medication types were uncertain. The authors noted that most studies did not use validated treatment satisfaction or symptom relief questionnaires.
Two reviewers were employed by Oxford PharmaGenesis Ltd.
Potential limitations in study quality, review processes and reporting of results imply that the authors' conclusions should be treated with caution. management of chronic disease. The authors noted that physicians tended to overestimate the benefit of proton pump inhibitor treatment in GERD.
Research: The authors proposed that future research should use validated questionnaires to measure patient satisfaction with GERD treatment using multi-item scales with balanced positive and negative items. Research should focus on other clinical end points (including healing of reflux oesophagitis, prevention of relapse and adverse effects in addition to changes in individual symptoms such as heartburn frequency and severity) which could contribute to improved patient care and long-term treatment success. They suggested that there was an unmet need for effective treatment in some patients that required further study.
